deferoxamine has been researched along with Pneumonia, Pneumocystis in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria." | 1.29 | Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. ( Chin, K; Clarkson, AB; Grady, RW; Merali, S; Weissberger, L, 1995) |
| "In a rat model of Pneumocystis carinii pneumonia, a 3-week infusion of deferoxamine producing concentrations in plasma of > or = 1." | 1.29 | Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. ( Chin, K; Clarkson, AB; Grady, RW; Merali, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merali, S | 4 |
| Chin, K | 3 |
| Grady, RW | 4 |
| Weissberger, L | 1 |
| Clarkson, AB | 5 |
| Del Angel, L | 1 |
| Armstrong, M | 1 |
| Turkel-Parrella, D | 1 |
| Williams, JH | 1 |
| Chen, LC | 1 |
| Gordon, T | 1 |
| Sarić, M | 1 |
| Kouides, PA | 1 |
| Slapak, CA | 1 |
| Rosenwasser, LJ | 1 |
| Miller, KB | 1 |
6 other studies available for deferoxamine and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.
Topics: Animals; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 1995 |
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Antifungal Agents; Chromatography, High Pressure Liquid; Deferoxamine; Lung; Mice; Pneumoni | 1995 |
Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.
Topics: Animals; Antifungal Agents; Deferoxamine; Lung; Pneumocystis; Pneumonia, Pneumocystis; Rats | 1996 |
Action of deferoxamine against Pneumocystis carinii.
Topics: Aerosols; Animals; Chelating Agents; Cytoplasm; Deferoxamine; Half-Life; Humans; Injections, Intrape | 2001 |
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Eflornithine; Female; Pneumonia, Pneumocystis; Random | 1990 |
Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy.
Topics: Adult; Deferoxamine; Humans; Male; Pneumonia, Pneumocystis; Thalassemia | 1988 |